EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY-NC 4.0

Pharmacovigilance Regulatory Requirements for the Natural Health Products (NHPs) Industry in World Health Organization-Defined High Health Expenditure Countries (2020): A Scoping Review

Xin Yi Lim, Sanyogita Ram, Shane Scahill, Joanne Barnes

Drug Safety · 2026

DOI: 10.1007/s40264-026-01674-6 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Drug Safety, 2026. Verfasst von Xin Yi Lim und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Auckland, 85 Park Rd, Grafton, Auckland, 1023, New Zealand. Hauptthemen laut MEDLINE: Pharmacovigilance, Biological Products, Drug-Related Side Effects and Adverse Reactions, Drug Industry. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Auckland Medical Research Foundation, University of Auckland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pharmacovigilance is the science and practice of safety monitoring for medicines-related problems; it is also applicable to a broader scope of health products, including natural health products (NHPs). The NHPs industry is a key stakeholder in pharmacovigilance for NHPs, but academic review of regulatory requirements concerning pharmacovigilance for the NHPs industry is limited. OBJECTIVES: To map, describe and compare regulatory requirements for the NHPs industry regarding pharmacovigilance for NHPs in selected international jurisdictions. METHODS: The top 30 countries/regions from the World Health Organization's (WHO) list of nations with the highest Current Health Expenditure in 2020 were identified. For these countries/regions, publicly accessible regulatory instruments describing pharmacovigilance requirements for the NHPs industry, available in English on official governmental websites and selected secondary resources, were sought. RESULTS: Regulatory documents from 12 countries/regions (Australia, Brazil, Canada, China, India, Japan, Republic of Korea, South Africa, Switzerland, UK, USA and the EU) were included. Definitions of NHPs vary across jurisdictions, while regulatory frameworks most clearly diverge between single medicine-based systems that include NHPs, and those that apply separate medicine- and food-based primary legislation to different NHP categories. Most included jurisdictions require the NHPs industry (i.e., product sponsors, market authorisation holders, registration/license holders, manufacturers) to report serious adverse drug reactions (ADRs) within 15 days of becoming aware of such reports. However, requirements for submitting foreign ADR reports, periodic safety update reports, conducting literature screening, and employing a Qualified Person for Pharmacovigilance differ. In jurisdictions that apply separate medicine- and food-based primary legislation to different NHP categories, pharmacovigilance requirements for the industry correspondingly vary. There are usually fewer (or no) requirements for products regulated as food compared with those included under medicine-based regulations. CONCLUSIONS: Pharmacovigilance regulatory requirements for the NHPs industry vary between and within countries/regions, primarily focusing on reporting serious ADRs. To support effective benefit-risk assessment of NHPs and safeguard public health, future policy-oriented research should assess the impact of these regulatory differences on industry practice and for pharmacovigilance for NHPs, examine requirements in countries not included here, and explore pathways towards international regulatory harmonisation. Pharmacovigilance is the science and practice of safety monitoring for medicines-related problems; it is also applicable to a broader scope of health products, including natural health products (NHPs). The NHPs industry (such as manufacturers, sponsors, market authorisation holders, registration/license holders) is a key stakeholder in pharmacovigilance for NHPs. This review discusses pharmacovigilance regulatory requirements for the NHPs industry in 11 countries (Australia, Brazil, Canada, China, India, Japan, Republic of Korea, South Africa, Switzerland, UK, USA) and the European Union (EU). Pharmacovigilance regulatory requirements vary between and within countries/regions. In countries/regions with regulations for NHPs, there are some requirements for the NHPs industry to report to the regulatory authority serious adverse drug reactions (ADRs) associated with NHPs, or some specific types of NHPs. Typically, serious ADRs must be reported by the NHPs industry within 15 days of becoming aware of the event. Also, within some countries/regions, the NHPs industry has fewer (or no) ADR reporting requirements for NHPs regulated as food than for those regulated as medicines. To support effective benefit–risk assessment of NHPs and safeguard public health, future policy work should examine how differences in regulations affect the industry and safety monitoring of these products, review regulations in countries not covered in this study, and explore strategies towards aligning regulations internationally.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacovigilanceBiological ProductsDrug-Related Side Effects and Adverse ReactionsDrug IndustryWorld Health OrganizationHumansAdverse Drug Reaction Reporting Systems

Substanzen

Biological Products

Autor:innen und Institutionen

  • School of Pharmacy, University of Auckland, 85 Park Rd, Grafton, Auckland, 1023, New Zealand.
  • School of Pharmacy, University of Auckland, 85 Park Rd, Grafton, Auckland, 1023, New Zealand. j.barnes@auckland.ac.nz.

Förderung

  • Auckland Medical Research Foundation
  • University of Auckland

Zitieren

APA

Lim, X. Y., Ram, S., Scahill, S., & Barnes, J. (2026). Pharmacovigilance Regulatory Requirements for the Natural Health Products (NHPs) Industry in World Health Organization-Defined High Health Expenditure Countries (2020): A Scoping Review. Drug Safety. https://doi.org/10.1007/s40264-026-01674-6

Vancouver

Lim XY, Ram S, Scahill S, Barnes J. Pharmacovigilance Regulatory Requirements for the Natural Health Products (NHPs) Industry in World Health Organization-Defined High Health Expenditure Countries (2020): A Scoping Review. Drug Safety. 2026. doi:10.1007/s40264-026-01674-6

BibTeX
@article{Lim2026,
  author = {Lim, Xin Yi and Ram, Sanyogita and Scahill, Shane and Barnes, Joanne},
  title = {Pharmacovigilance Regulatory Requirements for the Natural Health Products (NHPs) Industry in World Health Organization-Defined High Health Expenditure Countries (2020): A Scoping Review},
  journal = {Drug Safety},
  year = {2026},
  doi = {10.1007/s40264-026-01674-6}
}
Kostenlos starten →